<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36432196</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-3049</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>22</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>21</Day></PubDate></JournalIssue><Title>Molecules (Basel, Switzerland)</Title><ISOAbbreviation>Molecules</ISOAbbreviation></Journal><ArticleTitle>Neuropeptides, New Ligands of SARS-CoV-2 Nucleoprotein, a Potential Link between Replication, Inflammation and Neurotransmission.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">8094</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules27228094</ELocationID><Abstract><AbstractText>This work identifies new ligands of the nucleoprotein N of SARS-CoV-2 by in silico screening, which used a new model of N, built from an Alphafold model refined by molecular dynamic simulations. The ligands were neuropeptides, such as substance P (1-7) and enkephalin, bound at a large site of the C-terminal or associated with the N-terminal &#x3b2;-sheet. The BA4 and BA5 Omicron variants of N also exhibited a large site as in wt N, and an increased flexibility of the BA5 variant, enabling substance P binding. The binding sites of some ligands deduced from modeling in wt N were assessed by mutation studies in surface plasmon resonance experiments. Dynamic light scattering showed that the ligands impeded RNA binding to N, which likely inhibited replication. We suggest that the physiological role of these neuropeptides in neurotransmission, pain and vasodilation for cholecystokinin and substance P could be altered by binding to N. We speculate that N may link between viral replication and multiple pathways leading to long COVID-19 symptoms. Therefore, N may constitute a "danger hub" that needs to be inhibited, even at high cost for the host. Antivirals targeted to N may therefore reduce the risk of brain fog and stroke, and improve patients' health.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Henri</LastName><ForeName>Julien</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0772-8881</Identifier><AffiliationInfo><Affiliation>Laboratoire de Biologie Computationnelle et Quantitative, Institut de Biologie Paris-Seine, UMR-CNRS 7238, Sorbonne Universit&#xe9;, F-75005 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minder</LastName><ForeName>Laetitia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institut Europ&#xe9;en de Chimie et Biologie (IECB), CNRS, INSERM UAR 3033, US001, Univ. Bordeaux, F-33000 Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohanasundaram</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Saint Antoine Hospital, Centre de Recherche Saint Antoine, Sorbonne Universit&#xe9;, Biology and Cancer Therapeutics, INSERM U938, F-75231 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dilly</LastName><ForeName>S&#xe9;bastien</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Saint Antoine Hospital, Centre de Recherche Saint Antoine, Sorbonne Universit&#xe9;, Biology and Cancer Therapeutics, INSERM U938, F-75231 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goupil-Lamy</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biovia, Dassault Syst&#xe8;mes, 10 Rue Marcel Dassault, CS40501, CEDEX, F-78946 V&#xe9;lizy-Villacoublay, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Primo</LastName><ForeName>Carmelo</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0509-8399</Identifier><AffiliationInfo><Affiliation>CNRS, INSERM, ARNA, UMR 5320, U1212, IECB, Univ. Bordeaux, F-33000 Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slama Schwok</LastName><ForeName>Anny</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2703-9728</Identifier><AffiliationInfo><Affiliation>Saint Antoine Hospital, Centre de Recherche Saint Antoine, Sorbonne Universit&#xe9;, Biology and Cancer Therapeutics, INSERM U938, F-75231 Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CoVNucleovir</GrantID><Agency>The CovNucleovir from the faculty of Medicine of Sorbonne University</Agency><Country/></Grant><Grant><GrantID>CoVNucleovir</GrantID><Agency>The Sorbonne University Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Molecules</MedlineTA><NlmUniqueID>100964009</NlmUniqueID><ISSNLinking>1420-3049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009698">Nucleoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>33507-63-0</RegistryNumber><NameOfSubstance UI="D013373">Substance P</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009479">Neuropeptides</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009698" MajorTopicYN="N">Nucleoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013373" MajorTopicYN="N">Substance P</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009479" MajorTopicYN="Y">Neuropeptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">alphafold model and molecular dynamics</Keyword><Keyword MajorTopicYN="N">brain fog</Keyword><Keyword MajorTopicYN="N">metabolism</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">neuropeptides</Keyword><Keyword MajorTopicYN="N">neurotransmission</Keyword><Keyword MajorTopicYN="N">nucleocapsid or nucleoprotein</Keyword><Keyword MajorTopicYN="N">structure-based drug discovery</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the project results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>26</Day><Hour>1</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36432196</ArticleId><ArticleId IdType="pmc">PMC9698730</ArticleId><ArticleId IdType="doi">10.3390/molecules27228094</ArticleId><ArticleId IdType="pii">molecules27228094</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cubuk J., Alston J.J., Incicco J.J., Singh S., Stuchell-Brereton M.D., Ward M.D., Zimmerman M.I., Vithani N., Griffith D., Wagoner J.A., et al. The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA. Nat. Commun. 2021;12:1936. doi: 10.1038/s41467-021-21953-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21953-3</ArticleId><ArticleId IdType="pmc">PMC8007728</ArticleId><ArticleId IdType="pubmed">33782395</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinesh D.C., Chalupska D., Silhan J., Koutna E., Nencka R., Veverka V., Boura E. Structural basis of RNA recognition by the SARS-CoV-2 nucleocapsid phosphoprotein. PLoS Pathog. 2020;16:e1009100. doi: 10.1371/journal.ppat.1009100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009100</ArticleId><ArticleId IdType="pmc">PMC7735635</ArticleId><ArticleId IdType="pubmed">33264373</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S., Yang M., Hong Z., Zhang L., Huang Z., Chen X., He S., Zhou Z., Zhou Z., Chen Q., et al. Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. Acta Pharm. Sin. B. 2020;10:1228&#x2013;1238. doi: 10.1016/j.apsb.2020.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2020.04.009</ArticleId><ArticleId IdType="pmc">PMC7194921</ArticleId><ArticleId IdType="pubmed">32363136</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Q., West A.M.V., Silletti S., Corbett K.D. Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein. Protein Sci. 2020;29:1890&#x2013;1901. doi: 10.1002/pro.3909.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.3909</ArticleId><ArticleId IdType="pmc">PMC7405475</ArticleId><ArticleId IdType="pubmed">32654247</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q., Ming Z., Zhang L., et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science. 2020;368:779&#x2013;782. doi: 10.1126/science.abb7498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb7498</ArticleId><ArticleId IdType="pmc">PMC7164392</ArticleId><ArticleId IdType="pubmed">32277040</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein S., Cortese M., Winter S.L., Wachsmuth-Melm M., Neufeldt C.J., Cerikan B., Stanifer M.L., Boulant S., Bartenschlager R., Chlanda P. SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomography. Nat. Commun. 2020;11:5885. doi: 10.1038/s41467-020-19619-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19619-7</ArticleId><ArticleId IdType="pmc">PMC7676268</ArticleId><ArticleId IdType="pubmed">33208793</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K., Xiao F., Hu D., Ge W., Tian M., Wang W., Pan P., Wu K., Wu J. SARS-CoV-2 Nucleocapsid Protein Interacts with RIG-I and Represses RIG-Mediated IFN-&#x3b2; Production. Viruses. 2021;13:47. doi: 10.3390/v13010047.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13010047</ArticleId><ArticleId IdType="pmc">PMC7823417</ArticleId><ArticleId IdType="pubmed">33396605</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu J., Xu J., Zhang L., Shu T., Wu D., Huang M., Ren Y., Li X., Geng Q., Xu Y., et al. SARS-CoV-2-encoded nucleocapsid protein acts as a viral suppressor of RNA interference in cells. Sci. China Life Sci. 2020;63:1413&#x2013;1416. doi: 10.1007/s11427-020-1692-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11427-020-1692-1</ArticleId><ArticleId IdType="pmc">PMC7154568</ArticleId><ArticleId IdType="pubmed">32291557</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu S., Ye Q., Singh D., Cao Y., Diedrich J.K., Yates J.R., 3rd, Villa E., Cleveland D.W., Corbett K.D. The SARS-CoV-2 nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein. Nat. Commun. 2021;12:502. doi: 10.1038/s41467-020-20768-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20768-y</ArticleId><ArticleId IdType="pmc">PMC7820290</ArticleId><ArticleId IdType="pubmed">33479198</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Deitchman A.N., Torres L., Iyer N.S., Munter S.E., Nixon C.C., Donatelli J., Thanh C., Takahashi S., Hakim J., et al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep. 2021;36:109518. doi: 10.1016/j.celrep.2021.109518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109518</ArticleId><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian Y., Lei T., Patel P.S., Lee C.H., Monaghan-Nichols P., Xin H.-B., Qiu J., Fu M. Direct Activation of Endothelial Cells by SARS-CoV-2 Nucleocapsid Protein Is Blocked by Simvastatin. J. Virol. 2021;95:e01396-21. doi: 10.1128/JVI.01396-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01396-21</ArticleId><ArticleId IdType="pmc">PMC8577385</ArticleId><ArticleId IdType="pubmed">34549987</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Z., Cao Y., Liu W., Li J. The SARS-CoV-2 Nucleocapsid Protein and Its Role in Viral Structure, Biological Functions, and a Potential Target for Drug or Vaccine Mitigation. Viruses. 2021;13:1115. doi: 10.3390/v13061115.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13061115</ArticleId><ArticleId IdType="pmc">PMC8227405</ArticleId><ArticleId IdType="pubmed">34200602</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J.S., Alfajaro M.M., Chow R.D., Wei J., Filler R.B., Eisenbarth S.C., Wilen C.B. Nonsteroidal Anti-inflammatory Drugs Dampen the Cytokine and Antibody Response to SARS-CoV-2 Infection. J. Virol. 2021;95:e00014-21. doi: 10.1128/JVI.00014-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00014-21</ArticleId><ArticleId IdType="pmc">PMC8092681</ArticleId><ArticleId IdType="pubmed">33441348</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan X., Hao Q., Mu Y., Timani K.A., Ye L., Zhu Y., Wu J. Nucleocapsid protein of SARS-CoV activates the expression of cyclooxygenase-2 by binding directly to regulatory elements for nuclear factor-kappa B and CCAAT/enhancer binding protein. Int. J. Biochem. Cell Biol. 2006;38:1417&#x2013;1428. doi: 10.1016/j.biocel.2006.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2006.02.003</ArticleId><ArticleId IdType="pmc">PMC7108415</ArticleId><ArticleId IdType="pubmed">16546436</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia J., Tang W., Wang J., Lai D., Xu Q., Huang R., Hu Y., Gong X., Fan J., Shu Q., et al. SARS-CoV-2 N Protein Induces Acute Lung Injury in Mice via NF-&#x138;B Activation. Front. Immunol. 2021;12:791753. doi: 10.3389/fimmu.2021.791753.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.791753</ArticleId><ArticleId IdType="pmc">PMC8688532</ArticleId><ArticleId IdType="pubmed">34950152</ArticleId></ArticleIdList></Reference><Reference><Citation>Perico N., Cortinovis M., Suter F., Remuzzi G. Home as the new frontier for the treatment of COVID-19: The case for anti-inflammatory agents. Lancet Infect. Dis. 2022 doi: 10.1016/S1473-3099(22)00433-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00433-9</ArticleId><ArticleId IdType="pmc">PMC9411261</ArticleId><ArticleId IdType="pubmed">36030796</ArticleId></ArticleIdList></Reference><Reference><Citation>Terrier O., Dilly S., Pizzorno A., Chalupska D., Humpolickova J., Bou&#x159;a E., Berenbaum F., Quideau S., Lina B., F&#xe8;ve B., et al. Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus. Molecules. 2021;26:2593. doi: 10.3390/molecules26092593.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26092593</ArticleId><ArticleId IdType="pmc">PMC8124269</ArticleId><ArticleId IdType="pubmed">33946802</ArticleId></ArticleIdList></Reference><Reference><Citation>Terrier O., Dilly S., Pizzorno A., Henri J., Berenbaum F., Lina B., F&#xe8;ve B., Adnet F., Sabbah M., Rosa-Calatrava M., et al. Broad-spectrum antiviral activity of naproxen: From Influenza A to SARS-CoV-2 Coronavirus. bioRxiv. 2020 doi: 10.1101/2020.04.30.069922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.30.069922</ArticleId></ArticleIdList></Reference><Reference><Citation>Dilly S., Fotso Fotso A., Lejal N., Zedda G., Chebbo M., Rahman F., Companys S., Bertrand H.C., Vidic J., Noiray M., et al. From Naproxen Repurposing to Naproxen Analogues and Their Antiviral Activity against Influenza A Virus. J. Med. Chem. 2018;61:7202&#x2013;7217. doi: 10.1021/acs.jmedchem.8b00557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.8b00557</ArticleId><ArticleId IdType="pubmed">30028133</ArticleId></ArticleIdList></Reference><Reference><Citation>Lejal N., Tarus B., Bouguyon E., Chenavas S., Bertho N., Delmas B., Ruigrok R.W., Di Primo C., Slama-Schwok A. Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus. Antimicrob. Agents Chemother. 2013;57:2231&#x2013;2242. doi: 10.1128/AAC.02335-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.02335-12</ArticleId><ArticleId IdType="pmc">PMC3632891</ArticleId><ArticleId IdType="pubmed">23459490</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkai I., Mayer M.G., Hellmers L.M., Ning B., Huang Z., Monjure C.J., Coyne C., Silvestri R., Golden N., Hensley K., et al. Neuropathology and virus in brain of SARS-CoV-2 infected non-human primates. Nat. Commun. 2022;13:1745. doi: 10.1038/s41467-022-29440-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29440-z</ArticleId><ArticleId IdType="pmc">PMC8975902</ArticleId><ArticleId IdType="pubmed">35365631</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson E.J., Williams D.M., Walker A.J., Mitchell R.E., Niedzwiedz C.L., Yang T.C., Huggins C.F., Kwong A.S.F., Silverwood R.J., Di Gessa G., et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat. Commun. 2022;13:3528. doi: 10.1038/s41467-022-30836-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30836-0</ArticleId><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>Guseva S., Perez L.M., Camacho-Zarco A., Bessa L.M., Salvi N., Malki A., Maurin D., Blackledge M. (1)H, (13)C and (15)N Backbone chemical shift assignments of the n-terminal and central intrinsically disordered domains of SARS-CoV-2 nucleoprotein. Biomol. NMR Assign. 2021;15:255&#x2013;260. doi: 10.1007/s12104-021-10014-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12104-021-10014-x</ArticleId><ArticleId IdType="pmc">PMC7967780</ArticleId><ArticleId IdType="pubmed">33730325</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan W.H., Khan N., Mishra A., Gupta S., Bansode V., Mehta D., Bhambure R., Ansari M.A., Das S., Rathore A.S. Dimerization of SARS-CoV-2 nucleocapsid protein affects sensitivity of ELISA based diagnostics of COVID-19. Int. J. Biol. Macromol. 2022;200:428&#x2013;437. doi: 10.1016/j.ijbiomac.2022.01.094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2022.01.094</ArticleId><ArticleId IdType="pmc">PMC8762837</ArticleId><ArticleId IdType="pubmed">35051498</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y., Du N., Lei Y., Dorje S., Qi J., Luo T., Gao G.F., Song H. Structures of the SARS-CoV-2 nucleocapsid and their perspectives for drug design. EMBO J. 2020;39:e105938. doi: 10.15252/embj.2020105938.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020105938</ArticleId><ArticleId IdType="pmc">PMC7560215</ArticleId><ArticleId IdType="pubmed">32914439</ArticleId></ArticleIdList></Reference><Reference><Citation>Di D., Dileepan M., Ahmed S., Liang Y., Ly H. Recombinant SARS-CoV-2 Nucleocapsid Protein: Expression, Purification, and Its Biochemical Characterization and Utility in Serological Assay Development to Assess Immunological Responses to SARS-CoV-2 Infection. Pathogens. 2021;10:1039. doi: 10.3390/pathogens10081039.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10081039</ArticleId><ArticleId IdType="pmc">PMC8402198</ArticleId><ArticleId IdType="pubmed">34451501</ArticleId></ArticleIdList></Reference><Reference><Citation>Jumper J., Evans R., Pritzel A., Green T., Figurnov M., Ronneberger O., Tunyasuvunakool K., Bates R., Zidek A., Potapenko A., et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583&#x2013;589. doi: 10.1038/s41586-021-03819-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03819-2</ArticleId><ArticleId IdType="pmc">PMC8371605</ArticleId><ArticleId IdType="pubmed">34265844</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang M., He S., Chen X., Huang Z., Zhou Z., Zhou Z., Chen Q., Chen S., Kang S. Structural Insight Into the SARS-CoV-2 Nucleocapsid Protein C-Terminal Domain Reveals a Novel Recognition Mechanism for Viral Transcriptional Regulatory Sequences. Front. Chem. 2020;8:624765. doi: 10.3389/fchem.2020.624765.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2020.624765</ArticleId><ArticleId IdType="pmc">PMC7835709</ArticleId><ArticleId IdType="pubmed">33511102</ArticleId></ArticleIdList></Reference><Reference><Citation>Peronace C., Tallerico R., Colosimo M., Fazio M., Pasceri F., Talotta I., Panduri G., Pintomalli L., Oteri R., Calantoni V., et al. The First Identification in Italy of SARS-CoV-2 Omicron BA.4 Harboring KSF141_del: A Genomic Comparison with Omicron Sub-Variants. Biomedicines. 2022;10:1839. doi: 10.3390/biomedicines10081839.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10081839</ArticleId><ArticleId IdType="pmc">PMC9405011</ArticleId><ArticleId IdType="pubmed">36009386</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H., Xing N., Meng K., Fu B., Xue W., Dong P., Tang W., Xiao Y., Liu G., Luo H., et al. Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2. Cell Host Microbe. 2021;29:1788&#x2013;1801.e6. doi: 10.1016/j.chom.2021.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.11.005</ArticleId><ArticleId IdType="pmc">PMC8590493</ArticleId><ArticleId IdType="pubmed">34822776</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng W., Liu G., Ma H., Zhao D., Yang Y., Liu M., Mohammed A., Zhao C., Yang Y., Xie J., et al. Biochemical characterization of SARS-CoV-2 nucleocapsid protein. Biochem. Biophys. Res. Commun. 2020;527:618&#x2013;623. doi: 10.1016/j.bbrc.2020.04.136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.04.136</ArticleId><ArticleId IdType="pmc">PMC7190499</ArticleId><ArticleId IdType="pubmed">32416961</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechuga G.C., Souza-Silva F., Sacramento C.Q., Trugilho M.R.O., Valente R.H., Napoleao-Pego P., Dias S.S.G., Fintelman-Rodrigues N., Temerozo J.R., Carels N., et al. SARS-CoV-2 Proteins Bind to Hemoglobin and Its Metabolites. Int. J. Mol. Sci. 2021;22:9035. doi: 10.3390/ijms22169035.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22169035</ArticleId><ArticleId IdType="pmc">PMC8396565</ArticleId><ArticleId IdType="pubmed">34445741</ArticleId></ArticleIdList></Reference><Reference><Citation>Panagiotopoulos A., Tseliou M., Karakasiliotis I., Kotzampasi D.M., Daskalakis V., Kesesidis N., Notas G., Lionis C., Kampa M., Pirintsos S., et al. p-cymene impairs SARS-CoV-2 and Influenza A (H1N1) viral replication: In Silico predicted interaction with SARS-CoV-2 nucleocapsid protein and H1N1 nucleoprotein. Pharm. Res. Perspect. 2021;9:e00798. doi: 10.1002/prp2.798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.798</ArticleId><ArticleId IdType="pmc">PMC8204097</ArticleId><ArticleId IdType="pubmed">34128351</ArticleId></ArticleIdList></Reference><Reference><Citation>Amici C., Di Caro A., Ciucci A., Chiappa L., Castilletti C., Martella V., Decaro N., Buonavoglia C., Capobianchi M.R., Santoro M.G. Indomethacin has a potent antiviral activity against SARS coronavirus. Antivir. Ther. 2006;11:1021&#x2013;1030. doi: 10.1177/135965350601100803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/135965350601100803</ArticleId><ArticleId IdType="pubmed">17302372</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y. SARS-CoV-2 hijacks folate and one-carbon metabolism for viral replication. Nat. Commun. 2021;12:1676. doi: 10.1038/s41467-021-21903-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21903-z</ArticleId><ArticleId IdType="pmc">PMC7960988</ArticleId><ArticleId IdType="pubmed">33723254</ArticleId></ArticleIdList></Reference><Reference><Citation>Frere J.J., Serafini R.A., Pryce K.D., Zazhytska M., Oishi K., Golynker I., Panis M., Zimering J., Horiuchi S., Hoagland D.A., et al. SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations post recovery. Sci. Transl. Med. 2022;14:eabq3059. doi: 10.1126/scitranslmed.abq3059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abq3059</ArticleId><ArticleId IdType="pmc">PMC9210449</ArticleId><ArticleId IdType="pubmed">35857629</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricke-Hoch M., Stelling E., Lasswitz L., Gunesch A.P., Kasten M., Zapatero-Belinchon F.J., Brogden G., Gerold G., Pietschmann T., Montiel V., et al. Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease. PLoS ONE. 2021;16:e0255335. doi: 10.1371/journal.pone.0255335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0255335</ArticleId><ArticleId IdType="pmc">PMC8336874</ArticleId><ArticleId IdType="pubmed">34347801</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishk A., Pacheco M.P., Sauter T. DCcov: Repositioning of drugs and drug combinations for SARS-CoV-2 infected lung through constraint-based modeling. iScience. 2021;24:103331. doi: 10.1016/j.isci.2021.103331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.103331</ArticleId><ArticleId IdType="pmc">PMC8536485</ArticleId><ArticleId IdType="pubmed">34723158</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravichandran R., Mohan S.K., Sukumaran S.K., Kamaraj D., Daivasuga S.S., Ravi S., Vijayaraghavalu S., Kumar R.K. Author Correction: An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised COVID-19 patients. Sci. Rep. 2022;12:10389. doi: 10.1038/s41598-022-15107-8. Correction in Sci. Rep. 2022, 12, 6413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-15107-8</ArticleId><ArticleId IdType="pmc">PMC9208702</ArticleId><ArticleId IdType="pubmed">35725919</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah F.H., Lim K.H., Kim S.J. Do fever-relieving medicines have anti-COVID activity: An in silico insight. Future Virol. 2021;16:293&#x2013;300. doi: 10.2217/fvl-2020-0398.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fvl-2020-0398</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehboob R., Kurdi M., Bamaga A., Aldardeir N., Nasief H., Moshref L.H., Alsinani T., Rayes A.O., Jabbad R.H. Substance P/Neurokinin-1 Receptor, Trigeminal Ganglion, Latency, and Coronavirus Infection-Is There Any Link? Front. Med. 2021;8:727593. doi: 10.3389/fmed.2021.727593.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.727593</ArticleId><ArticleId IdType="pmc">PMC8637107</ArticleId><ArticleId IdType="pubmed">34869423</ArticleId></ArticleIdList></Reference><Reference><Citation>Salina A.C.G., Dos-Santos D., Rodrigues T.S., Fortes-Rocha M., Freitas-Filho E.G., Alzamora-Terrel D.L., Castro I.M.S., Fraga da Silva T.F.C., de Lima M.H.F., Nascimento D.C., et al. Efferocytosis of SARS-CoV-2-infected dying cells impairs macrophage anti-inflammatory functions and clearance of apoptotic cells. eLife. 2022;11:e74443. doi: 10.7554/eLife.74443.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.74443</ArticleId><ArticleId IdType="pmc">PMC9262386</ArticleId><ArticleId IdType="pubmed">35666101</ArticleId></ArticleIdList></Reference><Reference><Citation>Chau C.W., Sugimura R. COVID-19: Locked in a pro-inflammatory state. eLife. 2022;11:e80699. doi: 10.7554/eLife.80699.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.80699</ArticleId><ArticleId IdType="pmc">PMC9262384</ArticleId><ArticleId IdType="pubmed">35796529</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris J.A., Faust B., Gondin A.B., Damgen M.A., Suomivuori C.M., Veldhuis N.A., Cheng Y., Dror R.O., Thal D.M., Manglik A. Selective G protein signaling driven by substance P-neurokinin receptor dynamics. Nat. Chem. Biol. 2022;18:109&#x2013;115. doi: 10.1038/s41589-021-00890-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41589-021-00890-8</ArticleId><ArticleId IdType="pmc">PMC8712391</ArticleId><ArticleId IdType="pubmed">34711980</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehboob R., Lavezzi A.M. Neuropathological explanation of minimal COVID-19 infection rate in newborns, infants and children&#x2014;A mystery so far. New insight into the role of Substance P. J. Neurol. Sci. 2021;420:117276. doi: 10.1016/j.jns.2020.117276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.117276</ArticleId><ArticleId IdType="pmc">PMC7834711</ArticleId><ArticleId IdType="pubmed">33360484</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder G., Castro D.C., Bruchas M.R., Scherrer G. Endogenous and Exogenous Opioids in Pain. Annu. Rev. Neurosci. 2018;41:453&#x2013;473. doi: 10.1146/annurev-neuro-080317-061522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-neuro-080317-061522</ArticleId><ArticleId IdType="pmc">PMC6428583</ArticleId><ArticleId IdType="pubmed">29852083</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Chu C.H., Qian L., Chen S.H., Wilson B., Oyarzabal E., Jiang L., Ali S., Robinson B., Kim H.C., et al. Substance P exacerbates dopaminergic neurodegeneration through neurokinin-1 receptor-independent activation of microglial NADPH oxidase. J. Neurosci. Off. J. Soc. Neurosci. 2014;34:12490&#x2013;12503. doi: 10.1523/JNEUROSCI.2238-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2238-14.2014</ArticleId><ArticleId IdType="pmc">PMC4160779</ArticleId><ArticleId IdType="pubmed">25209287</ArticleId></ArticleIdList></Reference><Reference><Citation>Karamyan V.T. Between two storms, vasoactive peptides or bradykinin underlie severity of COVID-19? Physiol. Rep. 2021;9:e14796. doi: 10.14814/phy2.14796.</Citation><ArticleIdList><ArticleId IdType="doi">10.14814/phy2.14796</ArticleId><ArticleId IdType="pmc">PMC7941673</ArticleId><ArticleId IdType="pubmed">33687143</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattmann E., Bhalerao P., ShashiBhushan B.L., Nargundkar N., Lattmann P., Pillai K.S., Balaram P.N. Randomized, Comparative, Clinical Trial to Evaluate Efficacy and Safety of PNB001 in Moderate COVID-19 Patients. medRxiv. 2021 doi: 10.1101/2021.04.16.21255256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.04.16.21255256</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh V., Allawadhi P., Khurana A., Banothu A.K., Bharani K.K. Critical neurological features of COVID-19: Role of imaging methods and biosensors for effective diagnosis. Sens. Int. 2021;2:100098. doi: 10.1016/j.sintl.2021.100098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sintl.2021.100098</ArticleId><ArticleId IdType="pmc">PMC8117537</ArticleId><ArticleId IdType="pubmed">34766055</ArticleId></ArticleIdList></Reference><Reference><Citation>Heles M., Mrozkova P., Sulcova D., Adamek P., Spicarova D., Palecek J. Chemokine CCL2 prevents opioid-induced inhibition of nociceptive synaptic transmission in spinal cord dorsal horn. J. Neuroinflammation. 2021;18:279. doi: 10.1186/s12974-021-02335-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-021-02335-4</ArticleId><ArticleId IdType="pmc">PMC8638248</ArticleId><ArticleId IdType="pubmed">34857006</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L., Chalupsky K., Stefani E., Cai H. Mechanistic insights into folic acid-dependent vascular protection: Dihydrofolate reductase (DHFR)-mediated reduction in oxidant stress in endothelial cells and angiotensin II-infused mice: A novel HPLC-based fluorescent assay for DHFR activity. J. Mol. Cell. Cardiol. 2009;47:752&#x2013;760. doi: 10.1016/j.yjmcc.2009.07.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2009.07.025</ArticleId><ArticleId IdType="pmc">PMC2784291</ArticleId><ArticleId IdType="pubmed">19660467</ArticleId></ArticleIdList></Reference><Reference><Citation>Oak J.H., Cai H. Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice. Diabetes. 2007;56:118&#x2013;126. doi: 10.2337/db06-0288.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db06-0288</ArticleId><ArticleId IdType="pubmed">17192473</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara M., Tanaka K., Hirota Y. Immune response to influenza vaccine in healthy adults and the elderly: Association with nutritional status. Vaccine. 2005;23:1457&#x2013;1463. doi: 10.1016/j.vaccine.2004.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2004.09.022</ArticleId><ArticleId IdType="pubmed">15670881</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao S., Tang Y.S., Khan R.A., Zhang Y., Kusumanchi P., Stabler S.P., Jayaram H.N., Antony A.C. Influence of physiologic folate deficiency on human papillomavirus type 16 (HPV16)-harboring human keratinocytes in vitro and in vivo. J. Biol. Chem. 2012;287:12559&#x2013;12577. doi: 10.1074/jbc.M111.317040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.317040</ArticleId><ArticleId IdType="pmc">PMC3321005</ArticleId><ArticleId IdType="pubmed">22351779</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziganshyna S., Szczepankiewicz G., Kuehnert M., Schulze A., Liebert U.G., Pietsch C., Eulenburg V., Werdehausen R. Photodynamic Inactivation of SARS-CoV-2 Infectivity and Antiviral Treatment Effects In Vitro. Viruses. 2022;14:1301. doi: 10.3390/v14061301.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14061301</ArticleId><ArticleId IdType="pmc">PMC9229166</ArticleId><ArticleId IdType="pubmed">35746772</ArticleId></ArticleIdList></Reference><Reference><Citation>Courrol L.C., de Oliveira Silva F.R., Masilamani V. SARS-CoV-2, hemoglobin and protoporphyrin IX: Interactions and perspectives. Photodiagnosis Photodyn. Ther. 2021;34:102324. doi: 10.1016/j.pdpdt.2021.102324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pdpdt.2021.102324</ArticleId><ArticleId IdType="pmc">PMC8123386</ArticleId><ArticleId IdType="pubmed">33965601</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C., Michalska K., Jedrzejczak R., Maltseva N., Endres M., Godzik A., Kim Y., Joachimiak A. Crystal structure of RNA binding domain of nucleocapsid phosphoprotein from SARS coronavirus 2. Protein Data Bank. 2020 doi: 10.2210/pdb6VYO/pdb.</Citation><ArticleIdList><ArticleId IdType="doi">10.2210/pdb6VYO/pdb</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirdita M., Sch&#xfc;tze K., Moriwaki Y., Heo L., Ovchinnikov S., Steinegger M. ColabFold: Making protein folding accessible to all. Nat. Methods. 2022;19:679&#x2013;682. doi: 10.1038/s41592-022-01488-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-022-01488-1</ArticleId><ArticleId IdType="pmc">PMC9184281</ArticleId><ArticleId IdType="pubmed">35637307</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirdita M., Steinegger M., Soding J. MMseqs2 desktop and local web server app for fast, interactive sequence searches. Bioinformatics. 2019;35:2856&#x2013;2858. doi: 10.1093/bioinformatics/bty1057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bty1057</ArticleId><ArticleId IdType="pmc">PMC6691333</ArticleId><ArticleId IdType="pubmed">30615063</ArticleId></ArticleIdList></Reference><Reference><Citation>Darden T., York D., Pedersen L. Particle mesh Ewald: An N&#x22c5;log(N) method for Ewald sums in large systems. J. Chem. Phys. 1993;98:10089&#x2013;10092. doi: 10.1063/1.464397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1063/1.464397</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x160;ali A., Blundell T.L. Comparative protein modeling by satisfaction of spatial restraints. J. Mol. Biol. 1993;234:779&#x2013;815. doi: 10.1006/jmbi.1993.1626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jmbi.1993.1626</ArticleId><ArticleId IdType="pubmed">8254673</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Bruccoleri R.E., Olafson B.D., States D.J., Swaminathan S., Karplus M. CHARMM: A program for macromolec ular energy, minimization, and dynamics calculations. J. Comput. Chem. 1983;4:187&#x2013;217. doi: 10.1002/jcc.540040211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.540040211</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagistan Y., Kilinc E., Balci C.N. Cervical sympathectomy modulates the neurogenic inflammatory neuropeptides following experimental subarachnoid hemorrhage in rats. Brain Res. 2019;1722:146366. doi: 10.1016/j.brainres.2019.146366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2019.146366</ArticleId><ArticleId IdType="pubmed">31401069</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorente L., Mart&#xed;n M.M., Almeida T., Hern&#xe1;ndez M., Ramos L., Argueso M., C&#xe1;ceres J.J., Sol&#xe9;-Viol&#xe1;n J., Jim&#xe9;nez A. Serum substance P levels are associated with severity and mortality in patients with severe traumatic brain injury. Crit. Care. 2015;19:192. doi: 10.1186/s13054-015-0911-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-015-0911-z</ArticleId><ArticleId IdType="pmc">PMC4424826</ArticleId><ArticleId IdType="pubmed">25928056</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez A.N., Philipp M.T. Substance P and Antagonists of the Neurokinin-1 Receptor in Neuroinflammation Associated with Infectious and Neurodegenerative Diseases of the Central Nervous System. J. Neurol. Neuromedicine. 2016;1:29&#x2013;36. doi: 10.29245/2572.942x/2016/2.1020.</Citation><ArticleIdList><ArticleId IdType="doi">10.29245/2572.942x/2016/2.1020</ArticleId><ArticleId IdType="pmc">PMC4943220</ArticleId><ArticleId IdType="pubmed">27430034</ArticleId></ArticleIdList></Reference><Reference><Citation>Niemela V., Landtblom A.M., Nyholm D., Kneider M., Constantinescu R., Paucar M., Svenningsson P., Abujrais S., Burman J., Shevchenko G., et al. Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington&#x2019;s Disease. Mov. Disord. Off. J. Mov. Disord. Soc. 2021;36:481&#x2013;491. doi: 10.1002/mds.28391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28391</ArticleId><ArticleId IdType="pmc">PMC7984171</ArticleId><ArticleId IdType="pubmed">33247616</ArticleId></ArticleIdList></Reference><Reference><Citation>Otsuka K., Niimi A., Matsumoto H., Ito I., Yamaguchi M., Matsuoka H., Jinnai M., Oguma T., Takeda T., Nakaji H., et al. Plasma substance P levels in patients with persistent cough. Respiration. 2011;82:431&#x2013;438. doi: 10.1159/000330419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000330419</ArticleId><ArticleId IdType="pubmed">21846969</ArticleId></ArticleIdList></Reference><Reference><Citation>Smieszek S. Late Breaking Abstract&#x2014;Increased Substance P levels in COVID-19 hospitalized patients. Eur. Respir. J. 2021;58:OA4114. doi: 10.1183/13993003.congress-2021.OA4114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.congress-2021.OA4114</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyagi A., Daliri E.B.-M., Kwami Ofosu F., Yeon S.-J., Oh D.-H. Food-Derived Opioid Peptides in Human Health: A Review. Int. J. Mol. Sci. 2020;21:8825. doi: 10.3390/ijms21228825.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21228825</ArticleId><ArticleId IdType="pmc">PMC7700510</ArticleId><ArticleId IdType="pubmed">33233481</ArticleId></ArticleIdList></Reference><Reference><Citation>Boaventura P., Macedo S., Ribeiro F., Jaconiano S., Soares P. Post-COVID-19 Condition: Where Are We Now? Life. 2022;12:517. doi: 10.3390/life12040517.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life12040517</ArticleId><ArticleId IdType="pmc">PMC9029703</ArticleId><ArticleId IdType="pubmed">35455008</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>